Urinary bladder neoplasm
Therapeutic area
Nephrology
Rare disease
No
- Definition
- A benign or malignant, primary or metastatic neoplasm of the bladder. - 2003
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Urinary bladder neoplasm
- Therapeutic area
- Nephrology
- urinary bladder neoplasm
- bladder neoplasm
- bladder tumor
- bladder tumors
- bladder tumour
- bladder tumours
- neoplasm of bladder
- neoplasm of the bladder
- neoplasm of the urinary bladder
- neoplasm of urinary bladder
- tumor of bladder
- tumor of the bladder
- tumor of the urinary bladder
- tumor of urinary bladder
- tumour of bladder
- tumour of the bladder
- tumour of the urinary bladder
- tumour of urinary bladder
- urinary bladder neoplasm
- urinary bladder neoplasm (disease)
- urinary bladder neoplasms
- urinary bladder tumor
- urinary bladder tumors
- urinary bladder tumour
- urinary bladder tumours
- Severity
- Mild
- Nephrology
- Oncology
- MONDO ID
- MONDO:0004987
- Parent condition
- MONDO:0006026
Related records
Broader conditions (10)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Urinary bladder disorder
- Urinary system disorder
- Urinary system neoplasm
Narrower conditions (59)
- Bladder adenocarcinoma
- Bladder benign neoplasm
- Bladder carcinoma in situ
- Bladder clear cell adenocarcinoma
- Bladder colloid adenocarcinoma
- Bladder colonic type adenocarcinoma
- Bladder diffuse clear cell adenocarcinoma
- Bladder dome cancer
- Bladder flat intraepithelial lesion
- Bladder hepatoid adenocarcinoma
- Bladder inflammatory myofibroblastic tumor
- Bladder lateral wall cancer
- Bladder leiomyoma
- Bladder lymphoma
- Bladder mixed adenocarcinoma
- Bladder neck cancer
- Bladder papillary clear cell adenocarcinoma
- Bladder papillary urothelial carcinoma
- Bladder papillary urothelial neoplasm
- Bladder sarcoma
Trials (1,705)
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
- [68Ga] NOTA-SGC8 in the Staging of Bladder Cancer
- 177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
- 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
- 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
- 3 Tesla MRI in Patients With Bladder Cancer
- 3 Ultrasound Guided Plane Blocks for Perioperative Analgesia in Patients Undergoing Radical Cystectomy
- 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
- A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer
- A Beta-only IL-2 ImmunoTherapY Study
- A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
- A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer
Approved drugs (1)
- Erdafitinib
Drugs in development (31)
- Acetaminophen Phase 1
- Apaziquone Phase 3
- Avelumab Phase 2
- Balstilimab Phase 2
- Camrelizumab Phase 2
- Catumaxomab Phase 1
- Cetrelimab Phase 3
- Cisplatin Phase 3
- Detalimogene voraplasmid Phase 1
- Durvalumab Phase 3
- E-7766 Phase 1
- Ferumoxytol Early phase 1
- Fluorouracil Phase 3
- Gadobutrol Early phase 1
- Gemcitabine Phase 3
- Larotaxel Phase 3
- Lenalidomide Phase 2
- Linrodostat Phase 2
- Mitomycin Phase 3
- Nivolumab Phase 3
Other linked drugs (3)
- Aminolevulinic acid hydrochloride
- Epirubicin
- Rocuronium bromide